New Pill Cuts Mortality Risk in Half

Lung cancer claims the lives of millions of people each year, making it the leading cause of cancer-related deaths worldwide. Because of the disease’s great resistance to treatment, patients with this condition have historically had few therapeutic alternatives.

A worldwide study lasting more than a decade discovered that taking a pill on a daily basis can decrease lung cancer mortality in half. According to The Guardian, the pill osimertinib achieved “thrilling” and “unprecedented” results in a late-stage study, stunning researchers and oncologists.  

Researchers presented the findings of a study that lasted more than a decade and included participants from 26 countries at the annual meeting of the American Society for Clinical Oncology in Chicago. Mutations in the EGFR gene cause about 25% of lung cancer cases worldwide, with much higher rates in Asia, according to a study led by Yale University and reported by The Guardian. The clinical trial found that post-operative osimertinib medication reduced death risk by 51%.

This is a significant advancement because lung cancer kills more people than any other type of cancer, killing over 1.8 million people each year. Dr. Roy Herbst, deputy director of Yale Cancer Center and lead author of the study, was overjoyed with the findings, calling a 50% reduction in risk a significant achievement for a condition that has previously proven tough to treat. He emphasized the importance of osimertinib, a potent drug that has improved the outlook for patients with lung cancer.  

The study also discovered that osimertinib reduced the likelihood of cancer recurrence by half, indicating its potential as a game-changing treatment. This drug, according to Dr. Herbst, should be the gold standard for treating persons with EGFR-mutated lung cancer all over the world.  

The study included patients ranging in age from 30 to 86, with the vast majority being nonsmokers. In comparison to 78% of patients who received a placebo following tumor removal, 88% of osimertinib patients were still alive after five years. The survival effect was evident across all trial subgroups, including individuals with early and advanced lung cancer, as well as those who had previously received chemotherapy.  

Dr. Nathan Pennell, an American Society of Clinical Oncology specialist, called the findings “highly significant” and emphasized the outstanding improvement in overall survival. The study’s findings will almost certainly have far-reaching implications for how lung cancer is treated, providing hope to patients all over the world.  

Angela Terry, the head of the Lung Cancer Charity, was thrilled with the findings, calling them “hugely significant” and cited the 88% overall survival rate after five years as “incredibly positive news.” She emphasized the necessity of offering osimertinib to patients, a medication that has been demonstrated to be effective and well tolerated by patients. 


Leave a Reply